BQ-123
As of the edition of 20 October 2026, BQ-123 is a protein: stopped in 2021; acts on EDNRA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Protein
- Registered trials
- 14, 1 stopped early
- Disease areas
- Heart and blood vessels; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EDNRA | Endothelin-1 receptor | P25101 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 5 | 0 | 0 |
| Phase 1 | 6 | 4 | 1 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 14 |